ASCEND Therapeutics, Inc. to Present Phase 2 Data from Breast Tumor Cell Proliferation Study; Data Will Be Presented at the 26th Annual San Antonio Breast Cancer Symposium
HERNDON, Va., Nov. 24, 2003--ASCEND Therapeutics, Inc. announced today that it will present data from a Phase 2 dose-escalating study comparing the Company's percutaneous TamoGel(TM) (4-Hydroxytamoxifen gel) to orally administered tamoxifen.
The data will be presented at the 26th Annual San Antonio Breast
Cancer Symposium being held December 3 - 6, 2003 in San Antonio,
Date: Saturday, December 6, 2003
Time: 7:00 - 9:00 am (CST)
Presenters: Dana Hilt, MD, Chief Medical Officer, ASCEND
Philippe Rouanet, MD, Centre Val d'Aurelle, Montpellier,
Poster: Poster # 687
Session Title: Treatment: Neoadjuvent Chemotherapy
TamoGel(TM) is a percutaneously applied gel formulation of 4-
Hydroxytamoxifen (4-OHT) that is currently under investigation in a
variety of benign and malignant estrogen-dependent conditions by
ASCEND Therapeutics. 4-OHT is a metabolite of tamoxifen that is up
to 100 times more potent than tamoxifen in inhibiting breast cell
proliferation in vitro. (Malet, Cancer Research, 1988). TamoGel(TM)
is formulated as an enhanced hydroalcoholic gel for transdermal
delivery. I.e., the gel is applied directly to the surface of the
breast, where it is absorbed into the breast tissue.
About ASCEND Therapeutics
Based in Herndon, Virginia, ASCEND Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery and development of innovative therapeutic products for the treatment of underserved chronic conditions. ASCEND's initial product pipeline includes transdermal hydroalcoholic gel-based products in the areas of women's and men's health. ASCEND's gel product TamoGel(TM) is currently in two separate Phase 2 clinical trials for breast pain and breast density. DHT, its product for elderly hypogonadism, will begin Phase 2 trials in 2004.
Posted: November 2003